Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;24(7):238-246.
doi: 10.1007/s11926-022-01077-3. Epub 2022 May 3.

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

Kevin F Boehnke  1 , Winfried Häuser  2   3 , Mary-Ann Fitzcharles  4   5
Affiliations
Review

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

Kevin F Boehnke et al. Curr Rheumatol Rep. 2022 Jul.

Abstract

Purpose of review: This review will address the many uncertainties surrounding the medical use of cannabidiol (CBD). We will begin with an overview of the legal and commercial environment, examine recent preclinical and clinical evidence on CBD, explore questions concerning CBD raised by healthcare professionals and patients, investigate dosing regimens and methods of administration, and address current challenges in the accumulation of sound evidence.

Recent findings: CBD has potential for relief of symptoms of pain, sleep, and mood disturbance in rheumatology patients, but sound clinical evidence is lacking. CBD is safe when accessed from a regulated source, whereas wellness products are less reliable regarding content and contaminants. Dosing for symptom relief has not yet been established. As many rheumatology patients are trying CBD as a self-management strategy, the healthcare community must urgently accrue sound evidence for effect.

Keywords: Cannabidiol rheumatic disease; Musculoskeletal; Pain.

PubMed Disclaimer

Conflict of interest statement

KB sits on a data safety and monitoring commitee for Vireo Health in an unpaid capacity. MAF and WH report no conflict of interest involving the work under consideration.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO. Cannabidiol (CBD) Critical review report 2018 [22 Sept 2019]. Available from: https://www.who.int/medicines/access/controlled-substances/CannabidiolCr....
    1. Fitzcharles MA, Clauw DJ, Hauser W. A cautious hope for cannabidiol (CBD) in rheumatology care. Arthritis Care Res (Hoboken). 2020. (online ahead of print). - PubMed
    1. Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300–315. doi: 10.1016/j.jep.2018.09.004. - DOI - PubMed
    1. Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70(Pt B):288–91. doi: 10.1016/j.yebeh.2016.11.021. - DOI - PubMed
    1. Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697. doi: 10.3389/fpls.2019.00697. - DOI - PMC - PubMed

MeSH terms